体腔热灌注顺铂治疗恶性体腔积液的临床观察  

Clinical Efficacy of Thermic Perfusion of Cisplatin in Treatment of Malignant Effusion

作　　者：卢志文 卢光 黄树明 黄宪平 黄振 

机构地区：[1]广东省罗定市人民医院肿瘤科,广东罗定527200

出　　处：《中国医院用药评价与分析》2014年第10期870-872,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：2011年广东省云浮市科技计划项目(编号:WS 1114)

摘　　要：目的：观察体外循环热灌注化疗治疗恶性胸腹水的疗效及不良反应。方法：选择恶性胸腹水患者100例，按照随机数字表法分为治疗组及对照组。治疗组患者50例，采用HGGZ-102体腔循环热化疗系统行体腔热疗，腔内温度达41—43℃，给予顺铂50mg、地塞米松10mg注入体腔，体腔循环持续60min；对照组患者50例，给予体腔注入顺铂50mg。2组患者均进行1周2次的治疗，疗程为2周。结果：治疗组患者总有效率为76．0％（38／50）；对照组为46．O％（23／50），治疗组明显优于对照组（P〈0．05）；2组不良反应发生率相当。结论：体腔循环灌注热化疗治疗恶性胸腹水疗效好，不良反应可以耐受。OBJECTIVE：To evaluate the efficacy and side effects of extracorporeal circulation hyperthermic perfusion chemotherapy for malignant pleural effusion or ascites. METHODS： 100 cases of malignant pleural effusion or ascites were randomized to either treatment group or control group of 50 cases each. The treatment group received thermotherapy using HGGZ-102 body cavity circulating thermochemotherapy system with intra-cavity maintained at 41- 43 ℃ circulation maintained for 60 min and into the cavity cisplatin （50 mg） and dexamethasone （10 mg） were injected; while the control group were injected with cisplatin （50 mg） via body cavity. The medications were given twice a week for two consecutive weeks. RESULTS： The response rate in the treatment group was significantly higher than in the control group [ 76.0% （ 38/50 ） vs. 46.0% （23/50） ; P 〈 0.05 ） ; there was no statistically significant difference between the two groups in terms of the incidence of adverse reactions. CONCLUSIONS： Body cavity circumfusion thermochemotherapy is effective for malignant pleural effusion or ascites with tolerable adverse reactions.

关 键 词：恶性胸腹水 热灌注化疗 顺铂 

分 类 号：R979.1[医药卫生—药品]